Antibodies have become increasingly common in the therapeutic landscape against cancer and various infectious diseases. The ability to exploit the unique characteristics of antibodies in facilitating the delivery of pharmacological agents, such as PROTACs, to target cells has significant potential for its application to novel targets. At Rapid Novor, we support antibody drug discovery through de novo antibody sequencing and proteomics.
De novo protein sequencing of monoclonal and polyclonal antibodies allows for the evaluation of lead candidates with key insights into relevant CDR and framework sequences for antibody engineering. Rapid Novor utilizes a well-established mass spectrometry-based antibody sequencing service to sequence antibodies directly from the mass spectral data, without reference to genomic sequence information.
Our proteomic services for analyzing protein-protein interactions augment our protein sequencing services for abPROTACs design. HDX-MS epitope mapping service can characterize antibody-antigen protein complexes, to accurately determine linear, conformational, and structural epitopes. SPR kinetic binding analysis provides insights into the binding affinity, specificity, and association and dissociation rates of the abPROTACs to its target antigen. Kinetic analysis is critical during PROTAC design as ligands, linkers, and protein binding moieties can impact binding interactions and ternary complex formation.
To learn more about our services, reach out to our scientists.